Beijing Winsunny Pharmaceutical CO.LTD (601089) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Beijing Winsunny Pharmaceutical CO.LTD stock ¥9.57, price ¥15.69, that is 39.0% below the price, quality 59 out of 100. Rating: strongly overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
52‑month range ¥11.26 – ¥31.02 · fair‑value band ¥7.11 – ¥10.44 · the ¥15.69 price screens above the ¥9.57 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Beijing Winsunny Pharmaceutical CO.LTD in your weekly email
Every Wednesday you see whether Beijing Winsunny Pharmaceutical CO.LTD is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Beijing Foyou Pharma CO.,LTD engages in the research and development, production, and sale of pharmaceutical formulation and medical devices China.
Show moreShow less
The company offers chemical drugs; traditional Chinese medicine; raw materials; and medical devices, such as negative pressure drainage device, digital urine collection bags, dynamic urine output monitor, disposable pressure sensor, urodynamic monitoring device, nasal air filter, medical micro-mesh nebulizer, disposable atomizer, disposable oxygen mask, and disposable oxygen tubing.
It sells its products through medical institutions and retail outlets. The company's products cover cardiovascular system, chronic kidney disease, dermatology, digestive system, diabetes, neuropsychiatric system, and gynecology areas.
Beijing Foyou Pharma CO.,LTD was incorporated in 1999 and is headquartered in Beijing, China.
Stock analysis
Beijing Winsunny Pharmaceutical CO.LTD (601089) currently trades at ¥15.69, while our model-based Fair Value estimate is ¥9.57, 39% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥20.09 per share, and 7 of the 15 models we run sit above the ¥15.69 price.
Bear case: the Asset-Based group reads lowest at ¥3.97, and 8 of the 15 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥7.11 (bear) to ¥10.44 (bull), the price of ¥15.69 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Beijing Winsunny Pharmaceutical CO.LTD reported revenue of 3.5B CNY in FY2025 versus 2.8B CNY in FY2021, a compound +5.4%/yr. Reported net income was 469M CNY in FY2025, compounding +10.5%/yr from FY2021.
Key figures
Market cap 7.5B CNY (≈ $1.1B) Small · P/E ratio 18.7 · P/S ratio 2.10 · EPS (TTM) ¥0.8400 · Dividend yield 3.2% · Net margin 10.8% · Return on equity 10.7% · Return on assets (EBIT) 12.0% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −39%, 601089 screens richer than that median.
Fair Value models
Bear¥7.11Fair Value ¥9.57Bull¥10.44
Price ¥15.69 · Downside -39.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.2906 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.46/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+7.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.1%
Dividend (yield on the price)3.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 15%
Compare Beijing Winsunny Pharmaceutical CO.LTD with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside−39.0% · Below median
Profitability
Return on equity (12 months)10.7% · Above median
Return on assets9.5% · Top 25%
Net margin (12 months)10.8% · Above median
Operating margin (12 months)8.9% · Below median
Growth and dividend
Revenue growth (quarter YoY)11.9% · Above median
Dividend yield (12 months)3.2% · Above median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)18.7× · Cheaper than median
P/B1.99× · Pricier than median
P/S (12 months)2.10× · Cheaper than median
EV/EBITDA13.4× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)60· sector 25
PAST (return on equity)43· sector 29
HEALTH (low debt)100· sector 96
DIVIDEND (yield)64· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Beijing Winsunny Pharmaceutical CO.LTD (601089) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of ¥9.57 versus a price of ¥15.69, about 39% lower (overvalued).
What is the fair value of 601089?
Our model-based fair value for Beijing Winsunny Pharmaceutical CO.LTD is ¥9.57 (as of Nov 5, 2026), built from audited fundamentals. The current price: ¥15.69.
What is the quality score of 601089?
Beijing Winsunny Pharmaceutical CO.LTD has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beijing Winsunny Pharmaceutical CO.LTD (601089)?
Our model-based price target is the fair value of ¥9.57 (as of Nov 5, 2026) from 15 valuation models. Cautious scenario ¥7.11, optimistic scenario ¥10.44. It is a calculation from audited fundamentals, not an analyst target.
What is the Beijing Winsunny Pharmaceutical CO.LTD stock forecast for 2026?
Our models put fair value at ¥9.57, about 39% lower versus a price of ¥15.69 (overvalued). Cautious scenario ¥7.11, optimistic scenario ¥10.44. The calculation is refreshed regularly with new filings.
What is the revenue of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
Beijing Winsunny Pharmaceutical CO.LTD reported trailing-twelve-month revenue of about 3.6B CNY (latest available figure, as of Nov 5, 2026).
Does Beijing Winsunny Pharmaceutical CO.LTD pay a dividend?
Beijing Winsunny Pharmaceutical CO.LTD currently shows a dividend yield of 3.19% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Beijing Winsunny Pharmaceutical CO.LTD (601089) and when is the ex-dividend date?
Beijing Winsunny Pharmaceutical CO.LTD pays a dividend of ¥0.5 per share a year, a dividend yield of 3.2%. The last ex-dividend date was Jun 2, 2026. The payout ratio is 59.5% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beijing Winsunny Pharmaceutical CO.LTD it is ¥9.57 per share (as of Nov 5, 2026), against a price of ¥15.69. It is the blended result of 15 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Beijing Winsunny Pharmaceutical CO.LTD stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 601089 trades above its calculated fair value: price ¥15.69, fair value ¥9.57, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 601089?
No. The price is what the market pays today (¥15.69); the fair value is what the company's own numbers justify (¥9.57). For Beijing Winsunny Pharmaceutical CO.LTD the two are ¥6.12 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beijing Winsunny Pharmaceutical CO.LTD worth?
The market values Beijing Winsunny Pharmaceutical CO.LTD at about 7.5B CNY (market capitalisation, as of Nov 5, 2026). Per share that is ¥15.69; our models calculate a fair value of ¥9.57 per share.
What do the bullish and bearish scenarios say about 601089?
Our models span a range for Beijing Winsunny Pharmaceutical CO.LTD: cautious scenario ¥7.11, base ¥9.57, optimistic ¥10.44 per share (as of Nov 5, 2026, price ¥15.69). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 601089?
Beijing Winsunny Pharmaceutical CO.LTD trades at a price-to-earnings ratio of 18.7 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥9.57 is built from several models across several years. Other multiples: P/B 2.0, P/S 2.1, EV/EBITDA 13.4.
How solid is the balance sheet of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
Balance-sheet figures for Beijing Winsunny Pharmaceutical CO.LTD (as of Nov 5, 2026): return on equity 10.7%, debt of 0.00 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is 601089 from its 52-week high?
Beijing Winsunny Pharmaceutical CO.LTD trades at ¥15.69, about 47% below its 52-week high of ¥29.45 and 5% above the low of ¥14.95 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥9.57 is for.
Which stocks are comparable to Beijing Winsunny Pharmaceutical CO.LTD?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beijing Winsunny Pharmaceutical CO.LTD stock attractive at the current price?
The data as of Nov 5, 2026: price ¥15.69, calculated fair value ¥9.57 (−39%), Quality Score 59/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 601089 calculated?
We run Beijing Winsunny Pharmaceutical CO.LTD through 15 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥9.57 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Beijing Winsunny Pharmaceutical CO.LTD itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
The closing price on Nov 6, 2026 was ¥15.69. Our model-based fair value is ¥9.57, about 39% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beijing Winsunny Pharmaceutical CO.LTD right now?
The price sits above even our optimistic bull case (¥10.44). The favourable scenario is already priced in. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Beijing Winsunny Pharmaceutical CO.LTD
How large is the market capitalisation of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
The market capitalisation of Beijing Winsunny Pharmaceutical CO.LTD is 7.5B CNY (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
The price-to-sales ratio of Beijing Winsunny Pharmaceutical CO.LTD is 2.10 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
Earnings per share at Beijing Winsunny Pharmaceutical CO.LTD are ¥0.8400 (price ÷ EPS = P/E 18.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
The dividend yield of Beijing Winsunny Pharmaceutical CO.LTD is 3.2% (payout 59.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
The net margin of Beijing Winsunny Pharmaceutical CO.LTD is 10.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
The return on equity (ROE) of Beijing Winsunny Pharmaceutical CO.LTD is 10.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
On an EBIT basis the return on assets of Beijing Winsunny Pharmaceutical CO.LTD is 12.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beijing Winsunny Pharmaceutical CO.LTD (601089)?
The operating margin of Beijing Winsunny Pharmaceutical CO.LTD is 8.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beijing Winsunny Pharmaceutical CO.LTD (601089)?
Revenue at Beijing Winsunny Pharmaceutical CO.LTD is growing +11.9% versus a year earlier (3y avg +2.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Beijing Winsunny Pharmaceutical CO.LTD (601089)?
Earnings per share at Beijing Winsunny Pharmaceutical CO.LTD are growing −31.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Beijing Winsunny Pharmaceutical CO.LTD (601089) generate?
The free cash flow of Beijing Winsunny Pharmaceutical CO.LTD is −36.6M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Beijing Winsunny Pharmaceutical CO.LTD in the live analysis
One click puts Beijing Winsunny Pharmaceutical CO.LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026